For years, brand drug companies have been villainized for “evergreening” or manipulating the law to extend the period of exclusivity for drugs beyond their 20-year patent — a practice critics say unfairly prevents competition from generic drug companies and that has prompted legislators to consider significant reform to policies that govern the pharmaceutical industry. But an audit of more than…
Category: Prof. Erika Lietzan ⋅ Page 1
Prof. Lietzan publishes new paper on why medical device companies rarely renew patents
Professor Erika Lietzan, the William H. Pittman Professor of Law and Timothy J. Heinsz Professor of Law at Mizzou Law, recent published a new paper, “The Case of the Missing Device Patents, or: Why Device Patents Matter,” in the Fordham Intellectual Property, Media & Entertainment Law Journal. To read Prof. Lietzen’s article, visit:…
Prof. Erika Lietzan Re-appointed to ACUS, Named to Best Lawyer in America List
Erika Lietzan, the William H. Pittman Professor of Law & Timothy J. Heinsz Professor of Law was recently re-appointed to a two-year term as a public members of the Administrative Conference of the United States (ACUS). ACUS is an independent federal agency dedicated to improving the administrative process through consensus-driven applied research and providing nonpartisan expert advice and recommendations for…
Prof. Lietzen named Best Lawyer in America in FDA and Biotechnology & Life Sciences Law
Professor Erika Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology & Life Sciences. This marks the eighth year in a row for FDA Law and the fourteenth year in a row for Biotechnology Law. The Best Lawyers honor is meant to identify the top 5 percent of attorneys in the United States,…
Professor Lietzan elected as a member of the CREDIMI
Professor Erika Lietzan is a “Membre Associé” at the Centre de Recherche sur le Droit Des Marchés et des Investissements Internationaux (CREDIMI), which is part of the Faculty of Laws, Economics, and Politics of Dijon, within the University of Bourgogne in Dijon, France. The CREDIMI focuses on the study of the market, its functioning, and its players, including specific sectoral…
Professor Lietzan Appointed to Food and Drug Law Leadership Positions
Professor Erika Lietzan has been appointed co-chair of the annual conference of the Food and Drug Law Institute (FDLI). FDLI is a non-profit organization focused on food and drug law, supported by members from FDA, the food and drug bar, lawyers and regulatory specialists within the regulated industries, and academics specializing in FDA law. She has been a member of…
Professor Lietzan named a “Best Lawyer in America” for 2020
Professor Erika Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology & Life Sciences. This marks the seventh year in a row for FDA Law and the thirteenth year in a row for Biotechnology Law. The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United…
Professor Lietzan Among New Public Members of the Administrative Conference
Professor Erika Lietzan has been appointed as one of eight new public members of the Administrative Conference of the United States (ACUS). ACUS is an independent federal agency dedicated to improving the administrative process through consensus-driven applied research and providing nonpartisan expert advice and recommendations for federal agency procedures. Its public members are academics, practicing lawyers, and other experts drawn…
Professor Lietzan publishes in Yale Journal of Health Policy, Law, and Ethics
Professor Erika Lietzan has published a new article, Early Access to Unapproved Medicines in the United States and France, 19 Yale J. Health Pol’y L. & Ethics (2020). She, along with co-author Isabelle Moine-Dupuis, wrote about the new U.S. law on early access to experimental medicine. Lietzan and Moine-Dupuis explore the historical, legal, and cultural differences in the early access systems…
Professor Lietzan speaks at The Federalist Society’s COVID-19 & the Law Conference
Professor Erika Lietzan spoke at The Federalist Society’s COVID-19 & the Law Conference, contributing to the panel Regulation or “Don’t Let a Good Crisis Go to Waste.” She focused on decisions by regulators to de-regulate during the crisis — decisions to exercise enforcement discretion, to waive paperwork requirements, and to remove otherwise applicable restrictions — including decisions made by FDA…